Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…
Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…
Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment…
Conference Call October 20, 8:45am ESTQUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment…
Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this…
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has…
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved…
Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU,…
Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma…
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN…